BIAF.US bioAffinity Technologies, Inc.

Healthcare Biotechnology USA Stocks
2.28 USD
Close of Nov 13, 2026
2.17 80.70
Market cap
USD 4.15M
P/E
-
P/B
1.09x
ROE
-418.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BIAF.US undervalued?

Graham number

The Graham number of bioAffinity Technologies, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

bioAffinity Technologies, Inc. fundamental analysis

No fundamental analysis for bioAffinity Technologies, Inc. yet.

bioAffinity Technologies, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find c…

Full company profile